Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Pharma stocks slip;...

    Pharma stocks slip; Lupin top loser after posting Q4 earnings

    Written by Ruby Khatun Khatun Published On 2017-05-25T13:33:06+05:30  |  Updated On 25 May 2017 1:33 PM IST

    The pharma stocks have been trading with weakness on the Wednesday’s trading session. Lupin is the top loser in the Nifty pharma index trading lower by around 4% at Rs 1203 per share as of 1452 hours on Wednesday. The Nifty Pharma index is trading lower by 2.3% at 9422 levels.


    The Pharma major, Lupin has come out with its Q4 FY17 earnings. The profit after tax stood at Rs 380 Cr. The revenue at Rs 4,612 Cr. EBITDA Margin at 18.4%. Tax Expense at Rs 136.7 Cr.


    The other pharma stocks like Divi’s Lab, Glenmark, Cipla, Aurobindo Pharma, PEL, Dr Reddy’s and Sun Pharma were also trading in negative territory. The stocks Glaxosmith, Dr Reddy, Aurobindo Pharma, Glenmark and Divi’s Lab are trading close to their 52-week low.


    The major indices in the market, Nifty and Sensex are trading lower by 31 and 65 points respectively as of 1452 hours on Wednesday.


    Stock view:


    Lupin Ltd is currently trading at Rs 1227.3, down by Rs 21.7 or 1.74% from its previous closing of Rs 1249 on the BSE.


    The scrip opened at Rs 1250 and has touched a high and low of Rs 1275.75 and Rs 1168.1 respectively. So far 4024692(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 56413.72 crore.


    The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1750 on 29-Jul-2016 and a 52 week low of Rs 1231.5 on 23-May-2017. Last one week high and low of the scrip stood at Rs 1326.5 and Rs 1231.5 respectively.


    The promoters holding in the company stood at 46.69 % while Institutions and Non-Institutions held 41.24 % and 12.06 % respectively.


    The stock is currently trading below its 200 DMA.

    Aurobindo PharmaCiplaDivis LaboratoriesDr ReddyGlenmarkLupinnet profitPharma Stocksprofitprofit after taxSharesSun PharmaTax
    Source : PRESS RELEASE

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok